Evaluation of safety and pharmacokinetics of sodium 2,2 dimethylbutyrate, a novel short chain fatty acid derivative, in a phase 1, double-blind, placebo-controlled, single-dose, and repeat-dose studies in healthy volunteers

Journal of Clinical Pharmacology

Volumn 51, Issue 8, 2011, Pages 1186-1194

  Perrine, Susan P ^a,b,c   Wargin, William A ^e   Boosalis, Michael S ^c   Wallis, Wayne J ^a,b   Case, Sally ^a,b   Keefer, Jeffrey R ^d   Faller, Douglas V ^b   Welch, William C ^a,b   Berenson, Ronald J ^a,b  

^a Hemaquest Pharmaceuticals Inc   (United States)

^b Boston University School of Medicine ^*

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PK PM Associates LLC   (United States)

Author keywords

anemias; erythropoiesis; fetal hemoglobin; pharmacokinetic profiles; short chain fatty acids

Indexed keywords

BILIRUBIN; CREATINE KINASE; HEMOGLOBIN F; LACTATE DEHYDROGENASE; PLACEBO; SHORT CHAIN FATTY ACID; SODIUM 2,2 DIMETHYLBUTYRATE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; AREA UNDER THE CURVE; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPHONIA; ERYTHROID CELL; FEMALE; FOLLOW UP; HEADACHE; HEMATOCRIT; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE; SIDE EFFECT; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; BIOLOGICAL AVAILABILITY; BLOOD CELL COUNT; BUTYRIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; FEMALE; FETAL HEMOGLOBIN; FOOD-DRUG INTERACTIONS; HALF-LIFE; HEMATINICS; HUMANS; MALE; METABOLIC CLEARANCE RATE; PLASMA; RETICULOCYTES; URINE; YOUNG ADULT;

EID: 79960730507     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010379810     Document Type: Article

References (33)

1. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine (Baltimore). 2001 ; 80: 328-344 (Pubitemid 32879295)
2. Steinberg MH. Predicting clinical severity in sickle cell anemia. Brit J Haematol. 2005 ; 129: 465-481 (Pubitemid 40769896)
3. Perrine RP, Brown MJ, Clegg JB, Weatherall DJ, May A. Benign sickle anemia. Lancet. 1972 ; 2: 1163-1167
4. Bunn HF. Pathogenesis and treatment of sickle cell disease. N Engl J Med. 1997 ; 337: 762
5. Nagel RL, Bookchin RM, Johnson J, et al. Structural bases of the inhibitory effects of hemoglobin F and A2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA. 1979 ; 76: 670-672 (Pubitemid 9135654)
6. Perrine RP, Pembrey ME, John P, Perrine S, Shoup F. Natural history of sickle cell anemia in Saudi Arabs. A study of 270 subjects. Ann Intern Med. 1978 ; 88: 1-6 (Pubitemid 8265449)
7. Noguchi CT, Rodgers GP, Sergeant G, Schechter AN. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med. 1988 ; 318: 96-99 (Pubitemid 18029302)
8. Platt OS, Thorington BD, Brambilla DJ, et al. Pain in sickle cell disease. Rates and risk factors. N Eng J Med. 1991 ; 325: 11-16
9. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Eng J Med. 1994 ; 330: 1639-1644
10. Franco RS, Yasin Z, Palascak MB, Ciraolo P, Joiner CH, Rucknagel DL. The effect of fetal hemoglobin on the survival characteristics of sickle cells. Blood. 2006 ; 108: 1073-1076 (Pubitemid 44154647)
11. Powars D, Weiss JN, Chan LS, Schroeder WA. Is there a threshold level of fetal hemoglobin that ameliorates morbidity in sickle cell anemia?. Blood. 1984 ; 63: 921-926 (Pubitemid 14141316)
12. Kato GJ, Gladwin MT, Steinberg MH. Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007 ; 21: 37-47 (Pubitemid 46110926)
13. Rodgers GP, Dover GJ, Uyesaka N, Noguchi CT, Schechter AN, Nienhuis AW. Augmentation by erythropoietin of the fetal hemoglobin response to hydroxyurea in sickle cell disease. N Engl J Med. 1993 ; 328: 73-80
14. Chang YC, Smith KD, Moore RD, Serjeant GR, Dover GJ. An analysis of fetal hemoglobin variation in sickle cell disease: the relative contributions of the X-linked factors, beta-globin haplotypes, alpha-globin gene number, gender, and age. Blood. 1995 ; 85: 1111-1117
15. Perrine SP. Fetal globin induction: can it cure beta thalassemia?. Am Soc Hematol Educ. 2005 ;: 38-44
16. Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Eng J Med. 1993 ; 328: 81-86 (Pubitemid 23015533)
17. Little JA, Dempsey NJ, Tuchman M, Ginder GD. Metabolic persistence of fetal hemoglobin. Blood. 1995 ; 85: 1712
18. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 1999 ; 93: 1790-1797 (Pubitemid 29128478)
19. Collins AF, Pearson HA, Giardina P, McDonagh KT, Brusilow SW, Dover GJ. Oral sodium phenylbutyrate therapy in homozygous β thalassemia: A clinical trial. Blood. 1995 ; 85: 43-49
20. Perrine SP, Castaneda SA, Boosalis MS, White GL, Jones BM, Bohacek R. Induction of fetal globin in β-thalassemia: cellular obstacles and molecular progress. Ann NY Acad Sci. 2005 ; 1054: 1-9
21. Dover GJ, Brusilow SW, Charcahe S. Induction of HbF production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 1994 ; 84: 339-342
22. Nagel RL, Vichinsky E, Shah M, et al. F-reticulocytes response in sickle cell anemia treated with recombinant human erythropoietin: a double blind study. Blood. 1993 ; 81: 9-14 (Pubitemid 23013670)
23. Charache S, Dover GJ, Moyer MA, Moore JW. Hydroxyurea-induced augmentation of fetal hemoglobin production in subjects with sickle cell anemia. Blood. 1987 ; 69: 109
24. Steinberg MH, Lu ZH, Barton FB, Terrin ML, Charache S, Dover GJ. Fetal hemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood. 1997 ; 89: 1078-1088 (Pubitemid 27121303)
25. Steinberg MH, Barton F, Castro O, et al. Effects of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003 ; 289: 1645-1651 (Pubitemid 37430269)
26. Boosalis MS, Bandyopadhyay R, Bresnick EH, et al. Short chain fatty acid derivatives stimulate cell proliferation and induce STAT-5 activation. Blood. 2001 ; 97: 3259-3267
27. Pace BS, White GL, Dover GJ, Boosalis MS, Faller DV, Perrine SP. Short-chain fatty acid derivatives induce fetal globin expression and erythropoiesis in vivo. Blood. 2002 ; 100: 4640-4648 (Pubitemid 35429709)
28. Castaneda S, Boosalis MS, Emery D, Thies A, Faller DV, Perrine SP. Enhancement of growth and survival and alterations in bcl-family proteins in beta thalassemic erythroid progenitors by novel short chain fatty acid derivatives. Molecules. 2005 ; 35: 217-226 (Pubitemid 41267054)
29. Perrine SP. Fetal globin stimulant therapies in the beta- hemoglobinopathies: principles and current potential. Pediatr Annals. 2008 ; 37: 339-346 (Pubitemid 351847506)
30. Cappellini MD, Graziadei G, Ciceri L, et al. Oral Isobutyramide therapy in subjects with thalassemia intermedia: results of a phase II open study. Molecules. 2000 ; 26: 105-111 (Pubitemid 30331776)
31. Resar LMS, Segal JB, Fitzpatrick LK, et al. Induction of fetal hemoglobin synthesis in children with sickle cell anemia on low-dose oral sodium phenylbutyrate therapy. J Pediatr Hematol/Oncol. 2002 ; 24: 737-741 (Pubitemid 35448739)
32. Ikuta T, Kan YW, Swerdlow PS, Faller DV, Perrine SP. Alterations in protein-DNA interactions in the γ-globin gene promoter in response to butyrate therapy. Blood. 1998 ; 92: 2924-2933 (Pubitemid 28469108)
33. Emery DW, Yannaki E, Tubb J, Nishino T, Li Q, Stamatoyannopoulos G. development of virus vectors for gene therapy of beta chain hemoglobinopathies: flanking with a chromatin insulator reduces gamma globin gene silencing in vivo. Blood. 2002 ; 100: 2012-2019 (Pubitemid 35001231)